Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 09:00 ET | Source: Access Information Management Shared Services, LLC

Access Recognized by Inc. in its 2026 List of the Fastest Growing Private Companies in the Northeast

PEABODY, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Access, a leading global integrated information management solutions provider, is pleased to announce today that it has been recognized by Inc. in...
March 31, 2026 06:45 ET | Source: Scynexis

SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address...
March 31, 2026 06:40 ET | Source: Scynexis

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept...
March 14, 2026 13:10 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR ALERT: Camping World Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

The Camping World complaint alleges that Camping World overstated its ability to “surgically manage [its] inventory” to optimize profit.
March 10, 2026 11:51 ET | Source: Serve Robotics Inc.

Serve Robotics’ MJ Burk Chun Named a Top Female Founder by Inc.

As co-founder and VP of product and design, MJ Burk Chun has been instrumental in scaling Serve’s robots across the U.S. while fostering a culture of creativity and inclusion throughout the companyMJ...
March 04, 2026 16:20 ET | Source: Scynexis

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a...
February 26, 2026 08:23 ET | Source: Scynexis

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
January 28, 2026 08:00 ET | Source: Scynexis

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
January 21, 2026 08:00 ET | Source: Scynexis

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant,...
December 22, 2025 08:00 ET | Source: Scynexis

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...